| Title: |
Renal anaemia - CKD 1-5 |
| Authors: |
Fliser, Danilo; Shilo, Valery; Covic, Adrian; Besarab, Anatole; Provenzano, Robert; Duliege, Anne-Marie; Chen, Minjia; Tong, Sandra; Francisco, Carol; Gao, Hong-Ye; Polu, Krishna; De Francisco, Angel Lm; Macdougall, Iain; Schiller, Brigitte; Locatelli, Francesco; Wiecek, Andrzej; Tang, Helen; Mayo, Martha; Casadevall, Nicole; Stead, Richard; Taal, Maarten; Faller, Bernadette; Karras, Alexandre; Rowell, Richard; Eckardt, Kai-Uwe; Dusilova Sulkova, Sylvie; Arnaud, Stolz; Bruno, Paris; Arnaud, Guérard; Dorina, Visanica; Eric, Azoulay; Gérard, Mangenot; Cases, Aleix; Portolés, J.M.; Calls, J.; Martínez Castelao, A.; Sánchez-Guisande, D.; Segarra, A.; Tsubakihara, Yoshiharu; Saito, Akira; Af37702/Cct-001 Study Group; Af37702/Cct-101 Study Group; Martínez-Castelao, A.; Martínez-Castelao, Alberto; Cases, A.; Fort, J.; Bonal, J.; Fulladosa, X.; Galcerán, J.M.; Torregrosa, V.; Coll, E.; Minutolo, Roberto; Cozzolino, Mario; DI Iorio, Biagio; Polito, Pasquale; Santoro, Domenico; Manenti, Flavia; Nappi, Felice; Feriozzi, Sandro; Conte, Giuseppe; De Nicola, Luca; Mikhail, Ashraf; Daley, Richard; Yang, Alex; Canaud, Bernard; Rath, Thomas; Bartnicki, Piotr; Baj, Zbigniew; Majewska, Ewa; Rysz, Jacek; Fievet, Patrick; Assem, Maryam; Brazier, François; Xu, Xiaoli; Soltani, Oumeria Nadia; Demontis, Renato; Barsan, Liliana; Stancu, Simona; Stanciu, Ana; Capusa, Cristina; Petrescu, Ligia; Zugravu, Adrian; Mircescu, Gabriel; Malyszko, Jolanta Malyszko; Levin-Iaina, Nomy; Malyszko, Jacek; Glowinska, Irena; Koc-Zorawska, Ewa; Slotki, Itzachk; Mysliwiec, Michal; Grabowski, Doina; Blaga, Violeta; Dumitru, Daniela; Pchelin, Ivan; Shishkin, Alexander; Kus, Tulay; Usalan, Celalettin; Tiryaki, Ozlem; Chin, Ho Jun; Chae, Dong-Wan; Kim, Suhnggwon; Bertram, Hartmann; Keller, Frieder; Rumjon, Adam; Wood, Cheryl; Wilson, Paul; Khakoo, Shammim; Chai, Mee Onn; Macdougall, Iain C.; Nuria, Garcia-Fernandez; Maria Asuncion, Ferrer; Jose Maria, Mora-Gutierrez; Carmen, Calderon; Paloma Leticia, Martin-Moreno; Francisco Javier, Lavilla; Moniek, De Goeij; De Goeij, Moniek; Yvette, Meuleman; Diana, Grootendorst; Friedo, Dekker; Nynke, Halbesma; Lezaic, Visnja; Miljkovic, Branislava; Petkovic, Nenad; Maric, Ivko; Vucicevic, Katarina; Simic Ogrizovic, Sanja; Djukanovic, Ljubica; Fort, A.; DI Giulio, S; Galle, J; Kiss, I; Herlitz, H; Wirnsberger, G; Claes, K; Suranyi, M; Guerin, A; Winearls, C; Addison, J; D'souza, M; Froissart, M; Garrido, Patrícia; Teixeira, Margarida; Costa, Elísio; Rodrigues-Santos, Paulo; Parada, Belmiro; Belo, Luís; Alves, Rui; Teixeira, Frederico; Santos-Silva, Alice; Reis, Flávio; Fouqueray, B; Floris, Matteo; Conti, Maura; Cao, Riccardo; Pili, Gianfranco; Melis, Patrizia; Matta, Valeria; Murgia, Efisio; Atzeni, Alice; Binda, Valentina; Angioi, Andrea; Peri, Marcella; Pani, Antonello; Belo, Diogo; Diamond, Susan; Martin, Edouard; Sun, Chao; Lee, Tyson; Saikali, Khalil; Franco, Marietta; Leong, Robert; Neff, Thomas; Yu, Kin-Hung Peony; Tiranathanagul, Khajohn; Praditpornsilpa, Kearkiat; Katavetin, Pisut; Kanjanabuch, Talerngsak; Avihingsanon, Yingyos; Tungsanga, Kriang; Eiam-Ong, Somchai; Percheson, Paul; Potamianou, Anna; Foucher, Arnaud; Fife, Daniel; Vercammen, Els; Prims Study Group |
| Publisher Information: |
Oxford University Press |
| Publication Year: |
2012 |
| Collection: |
HighWire Press (Stanford University) |
| Subject Terms: |
Abstracts |
| Description: |
Introduction and Aims: Hemoglobin (Hb) stability with C.E.R.A. once-monthly (QM) was evaluated in high risk patients with chronic kidney disease (CKD) on dialysis switched from shorter-acting erythropoiesis-stimulating agents (ESAs). Methods: Adult CKD patients on dialysis were converted to C.E.R.A. QM to achieve a target Hb of 10.0–12.0 g/dL (5 studies), 10.5–12.5 g/dL (3 studies), 11.0–12.5 g/dL and 11–13 g/dL (one study each). High risk (HR) and low risk (LR) subgroups were defined on the basis of therapy parameters before switching: epoetin or darbepoetin alfa dose (=8000 IU or 40 μg, respectively), average Hb at screening (below the 40% percentile [ P60] for LR). The ratio of dose and achieved Hb at screening >P60 (HR), or Hb fluctuation >P60 (HR) were defined by the same parameters. Cardiovascular (CV) risk groups were defined by pre-existing cardiac risk factors (diabetes or cardiac disorder), or through >P60 N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. Treatment switchover was followed by a 16-week titration and an 8-week evaluation period. Hb parameters, dosing and safety in the evaluation period were compared. Results: Patients (N=1577); median age 63 (range: 19–93) years were classified into HR/LR subgroups as shown in the table. Table 1 *abaseline NT-proBNP values not available for one trial *p |
| Document Type: |
text |
| File Description: |
text/html |
| Language: |
English |
| Relation: |
http://ndt.oxfordjournals.org/cgi/content/short/27/suppl_2/ii133; http://dx.doi.org/10.1093/ndt/gfs217 |
| DOI: |
10.1093/ndt/gfs217 |
| Availability: |
http://ndt.oxfordjournals.org/cgi/content/short/27/suppl_2/ii133; https://doi.org/10.1093/ndt/gfs217 |
| Rights: |
Copyright (C) 2012, European Renal Association - European Dialysis and Transplant Association |
| Accession Number: |
edsbas.C5E8A87C |
| Database: |
BASE |